Jump to content

Cyanonilutamide

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Fswitzer4 (talk | contribs) at 18:57, 1 March 2022 (Added UNII). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Cyanonilutamide
Clinical data
Other namesRU-56279
Drug classNonsteroidal antiandrogen
Identifiers
  • 4-(4,4-Dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H10F3N3O2
Molar mass297.237 g·mol−1
3D model (JSmol)
  • CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)C#N)C(F)(F)F)C
  • InChI=1S/C13H10F3N3O2/c1-12(2)10(20)19(11(21)18-12)8-4-3-7(6-17)9(5-8)13(14,15)16/h3-5H,1-2H3,(H,18,21)
  • Key:CYCKLVAQENOQPG-UHFFFAOYSA-N

Cyanonilutamide (developmental code name RU-56279) is a nonsteroidal antiandrogen which was never marketed.[1][2] Both RU-56187 and RU-58841 appear to be prodrugs of cyanonilutamide in vivo in animals.[2] It has relatively low affinity for the androgen receptor but nonetheless shows significant antiandrogenic activity in animals.[2]

See also

References

  1. ^ Gryder BE, Akbashev MJ, Rood MK, Raftery ED, Meyers WM, Dillard P, Khan S, Oyelere AK (November 2013). "Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors". ACS Chem. Biol. 8 (11): 2550–60. doi:10.1021/cb400542w. PMC 3836611. PMID 24004176.
  2. ^ a b c Cousty-Berlin D, Bergaud B, Bruyant MC, Battmann T, Branche C, Philibert D (October 1994). "Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: relation of their systemic activity to the formation of a common metabolite". J. Steroid Biochem. Mol. Biol. 51 (1–2): 47–55. doi:10.1016/0960-0760(94)90114-7. PMID 7947350. S2CID 29752252.